FDA approves Blujepa for urinary tract infections, first new antibiotic in nearly 30 years.

The FDA has approved Blujepa (gepotidacin) for treating uncomplicated urinary tract infections (uUTIs) in women and children aged 12 and older, weighing at least 40 kg. This new oral antibiotic is the first of its kind in nearly three decades for uUTIs, addressing the growing issue of antibiotic resistance. Clinical trials showed Blujepa performed as well as or better than existing treatments, with common side effects including diarrhea and nausea. Blujepa targets uUTIs caused by specific bacteria and is expected to be available later this year.